An RNA medicine developed by Regeneron Pharmaceuticals and Alnylam Pharmaceuticals helped control symptoms of the chronic ...

Lilly has now completed the third Phase 3 trial necessary to support its FDA application. Besides the obesity Phase 3, Lilly ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.